Cover Image

Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection....

Full description

Saved in:
Bibliographic Details
Main Authors: Yurdaydin, Cihan (Author) , Urban, Stephan (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: Journal of hepatology
Year: 2019, Volume: 70, Issue: 5, Pages: 1008-1015
ISSN:1600-0641
DOI:10.1016/j.jhep.2018.12.022
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/j.jhep.2018.12.022
Get full text
Author Notes:Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J. Gane, Robert G. Gish, Jeffrey S. Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer, on behalf of the Hepatitis Delta International Network (HDIN)

MARC

LEADER 00000caa a2200000 c 4500
001 1666111309
003 DE-627
005 20230427154335.0
007 cr uuu---uuuuu
008 190522s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.jhep.2018.12.022  |2 doi 
035 |a (DE-627)1666111309 
035 |a (DE-599)KXP1666111309 
035 |a (OCoLC)1341225235 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Yurdaydin, Cihan  |e VerfasserIn  |0 (DE-588)1186852933  |0 (DE-627)1666112194  |4 aut 
245 1 0 |a Treating chronic hepatitis delta  |b the need for surrogate markers of treatment efficacy  |c Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J. Gane, Robert G. Gish, Jeffrey S. Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer, on behalf of the Hepatitis Delta International Network (HDIN) 
264 1 |c 2019 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.05.2019 
520 |a Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials. 
650 4 |a Hepatitis D 
650 4 |a New treatment approaches 
650 4 |a Surrogate marker 
650 4 |a Treatment endpoints 
700 1 |a Urban, Stephan  |e VerfasserIn  |0 (DE-588)1060263599  |0 (DE-627)79935399X  |0 (DE-576)174162049  |4 aut 
773 0 8 |i Enthalten in  |t Journal of hepatology  |d Amsterdam [u.a.] : Elsevier Science, 1985  |g 70(2019), 5, Seite 1008-1015  |h Online-Ressource  |w (DE-627)320984486  |w (DE-600)2027112-8  |w (DE-576)093888856  |x 1600-0641  |7 nnas  |a Treating chronic hepatitis delta the need for surrogate markers of treatment efficacy 
773 1 8 |g volume:70  |g year:2019  |g number:5  |g pages:1008-1015  |g extent:8  |a Treating chronic hepatitis delta the need for surrogate markers of treatment efficacy 
856 4 0 |u http://dx.doi.org/10.1016/j.jhep.2018.12.022  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190522 
993 |a Article 
994 |a 2019 
998 |g 1060263599  |a Urban, Stephan  |m 1060263599:Urban, Stephan  |d 910000  |d 911700  |e 910000PU1060263599  |e 911700PU1060263599  |k 0/910000/  |k 1/910000/911700/  |p 18 
999 |a KXP-PPN1666111309  |e 3478847613 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"subtitle":"the need for surrogate markers of treatment efficacy","title":"Treating chronic hepatitis delta","title_sort":"Treating chronic hepatitis delta"}],"relHost":[{"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1985","dateIssuedDisp":"1985-","publisher":"Elsevier Science ; Wiley-Blackwell"}],"part":{"extent":"8","year":"2019","volume":"70","text":"70(2019), 5, Seite 1008-1015","pages":"1008-1015","issue":"5"},"language":["eng"],"note":["Gesehen am 18.02.2020"],"recId":"320984486","disp":"Treating chronic hepatitis delta the need for surrogate markers of treatment efficacyJournal of hepatology","pubHistory":["1.1985 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"subtitle":"official journal of the European Association for the Study of the Liver","title":"Journal of hepatology","title_sort":"Journal of hepatology"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2027112-8"],"issn":["1600-0641"],"eki":["320984486"]}}],"physDesc":[{"extent":"8 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1016/j.jhep.2018.12.022"],"eki":["1666111309"]},"person":[{"given":"Cihan","role":"aut","display":"Yurdaydin, Cihan","family":"Yurdaydin"},{"display":"Urban, Stephan","family":"Urban","given":"Stephan","role":"aut"}],"name":{"displayForm":["Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J. Gane, Robert G. Gish, Jeffrey S. Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer, on behalf of the Hepatitis Delta International Network (HDIN)"]},"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"recId":"1666111309","language":["eng"],"note":["Gesehen am 22.05.2019"]} 
SRT |a YURDAYDINCTREATINGCH2019 

Similar Items